ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: musculoskeletal disease

Case Report: Drug-Induced Lupus

Haseeb Chaudhary, MD, Prem Parajuli, MD, & Devy Setyono, MD  |  September 14, 2021

The incidence of drug-induced lupus continues to rise as clinicians expand their therapeutic armamentarium. An estimated 15,000–30,000 cases of drug-induced lupus occur every year in the U.S. alone.1 It is a well-known, but rare, complication of commonly used medications, such as anti-hypertensive, anti-arrhythmic and anti-epileptic drugs, as well as biologic and immune checkpoint therapies.2,3 The…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:cardiac tamponadedrug-induced lupusphenytoin

Case Report: Reactive Arthritis Following COVID-19

Samuel C. Purkey, DO, James Z. Drew, MD, & Marcum Collins, MD  |  September 14, 2021

SARS-CoV-2, or COVID-19, is a complex disease entity that continues to evolve. Physicians, researchers and scientists alike have worked tirelessly to tackle this beast in its short existence; however, we are reminded daily that there is more to this virus than meets the eye. It is well known that COVID-19 can cause acute respiratory failure…

Filed under:Conditions Tagged with:COVID-19Reactive arthritisTenosynovitis

2 Cases of SLE-Associated Diffuse Alveolar Hemorrage

2 Cases of SLE-Associated Diffuse Alveolar Hemorrhage

Abhimanyu Amarnani, MD, PhD, Nicole K. Zagelbaum Ward, DO, MPH, Lauren Mathias, MD, Nathan Lim, MD, Baljeet Rai, MD, Sky Wang, MD, & William Stohl, MD, PhD  |  August 12, 2021

Pulmonary manifestations in patients with systemic lupus erythematosus (SLE) include pleuritis, acute pneumonitis, interstitial lung disease, pulmonary arterial hypertension, shrinking lung syndrome and diffuse alveolar hemorrhage (DAH). DAH is a rare, but devastating, complication of SLE, with high mortality rates. The incidence of DAH in SLE ranges from 0.6% to 5.4%, but the mortality rate…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:case reportdiffuse alveolar hemorrhage

Colchicine: An Ancient Drug with Modern Uses

Ibrahem Salloum, MD, & Deepan S. Dalal, MD, MPH  |  August 11, 2021

Discovered more than 3,000 years ago, colchicine is one of the oldest drugs still in use today. Like most old remedies, colchicine is a chemical substance found in many plants, most notably in colchicum autumnale, known as wild saffron or autumn crocus. It was mentioned in the oldest Egyptian medical text, Ebers Papyrus (circa 1550…

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:anti-inflammatoryColchicinedrug treatmentGoutinflammation

2022 Physician Fee Schedule Proposed Rule Released

From the College  |  July 20, 2021

In the proposed rule released July 13, the ACR is encouraged by the continued implementation of evaluation and management reimbursement adjustments to better reflect the work and expertise needed to treat complex patient populations, the extension of many telehealth flexibilities and the inclusion of the ACR’s proposed MACRA MIPS Value Pathway for rheumatology.

Filed under:From the CollegePractice Support Tagged with:Physician Fee Schedule (PFS)

Updates in Juvenile Dermatomyositis: Pathogenesis & Patient Care

Jason Liebowitz, MD, FACR  |  July 17, 2021

Experts provided an update on juvenile dermatomyositis, discussing patient care, treatment options and the pathogenesis of disease.

Filed under:ConditionsMeeting Reports Tagged with:juvenile dermatomyositisPathogenesisPediatric RheumatologyPediatric Rheumatology SymposiumPRSYM

Achieving Excellence in Pediatric Rheumatology Clinical Care

Jason Liebowitz, MD, FACR  |  July 17, 2021

PRSYM—At its heart, the practice of medicine in all forms is specifically centered on delivering compassionate, thoughtful and evidence-based clinical care. In the world of pediatric rheumatology, a range of issues, such as chronic pain, reproductive health and transitioning to adult providers, are of utmost importance to patients and physicians alike. These topics were addressed…

Filed under:ConditionsMeeting ReportsPain SyndromesPediatric Conditions Tagged with:Chronic painpatient carePediatricPediatric RheumatologyPediatric Rheumatology SymposiumPRSYMreproductive healthtransition

Manifestations of JIA: JIA-Associated Uveitis, sJIA & Lung Involvement in sJIA

Jason Liebowitz, MD, FACR  |  July 16, 2021

JIA can manifest in a variety of ways. Experts discuss the implications of uveitis, systemic disease and lung involvement in sJIA.

Filed under:ConditionsMeeting Reports Tagged with:eyesJIA-associated uveitisjuvenile idiopathic arthritis (JIA)lungsPediatric RheumatologyPediatric Rheumatology SymposiumPRSYMsJIAsJIA-associated lung disease

3 Educators Offer Lessons Learned on Rheumatology Training

Leslie Kahl, MD, Sheryl Mascarenhas, MD, & Rachel M. Wolfe, MD  |  July 15, 2021

Leslie Kahl, MD, on Coaching I have been an academic clinician-educator for my entire career and, like most of my colleagues, have been called upon to advise, mentor and coach countless trainees and junior faculty members. Unlike most clinician-educators, though, I also served as associate dean for student affairs at Washington University School of Medicine,…

Filed under:Education & Training Tagged with:FellowsFellows-in-Trainingfellowship program director

The Power of Mentorship in the Cultivation of Advanced Practice Providers

Sara Kellahan, MSN, APRN, AGPCNP-C  |  July 15, 2021

“The task of the modern educator is not to cut down jungles but to irrigate deserts,” said mid-20th century scholar and writer C.S. Lewis. Although he was speaking to the importance of the holistic education of students, the same idea rings true for a 21st century nurse practitioner (NP) new to rheumatology. Indeed, the care…

Filed under:Education & TrainingPractice SupportResearch RheumWorkforce Tagged with:Advanced Practice CliniciansRheumatology Research Foundation

  • « Previous Page
  • 1
  • …
  • 44
  • 45
  • 46
  • 47
  • 48
  • …
  • 95
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences